Literature DB >> 27581982

Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.

Masaharu Iwasaki1, Cherie T Ng1, Beatrice Cubitt1, Juan C de la Torre2.   

Abstract

Several arenaviruses, chiefly Lassa virus (LASV), cause hemorrhagic fever disease in humans and pose serious public health concerns in their regions of endemicity. Moreover, mounting evidence indicates that the worldwide-distributed prototypic arenavirus, lymphocytic choriomeningitis virus (LCMV), is a neglected human pathogen of clinical significance. We have documented that a recombinant LCMV containing the glycoprotein (GPC) gene of LASV within the backbone of the immunosuppressive clone 13 (Cl-13) variant of the Armstrong strain of LCMV (rCl-13/LASV-GPC) exhibited Cl-13-like growth properties in cultured cells, but in contrast to Cl-13, rCl-13/LASV-GPC was unable to establish persistence in immunocompetent adult mice, which prevented its use for some in vivo experiments. Recently, V459K and K461G mutations within the GP2 cytoplasmic domain (CD) of rCl-13/LASV-GPC were shown to increase rCl-13/LASV-GPC infectivity in mice. Here, we generated rCl-13(GPC/VGKS) by introducing the corresponding revertant mutations K465V and G467K within GP2 of rCl-13 and we show that rCl-13(GPC/VGKS) was unable to persist in mice. K465V and G467K mutations did not affect GPC processing, virus RNA replication, or gene expression. In addition, rCl-13(GPC/VGKS) grew to high titers in cultured cell lines and in immunodeficient mice. Further analysis revealed that rCl-13(GPC/VGKS) infected fewer splenic plasmacytoid dendritic cells than rCl-13, yet the two viruses induced similar type I interferon responses in mice. Our findings have identified novel viral determinants of Cl-13 persistence and also revealed that virus GPC-host interactions yet to be elucidated critically contribute to Cl-13 persistence. IMPORTANCE: The prototypic arenavirus, lymphocytic choriomeningitis virus (LCMV), provides investigators with a superb experimental model system to investigate virus-host interactions. The Armstrong strain (ARM) of LCMV causes an acute infection, whereas its derivative, clone 13 (Cl-13), causes a persistent infection. Mutations F260L and K1079Q within GP1 and L polymerase, respectively, have been shown to play critical roles in Cl-13's ability to persist in mice. However, there is an overall lack of knowledge about other viral determinants required for Cl-13's persistence. Here, we report that mutations K465V and G467K within the cytoplasmic domain of Cl-13 GP2 resulted in a virus, rCl-13(GPC/VGKS), that failed to persist in mice despite exhibiting Cl-13 wild-type-like fitness in cultured cells and immunocompromised mice. This finding has uncovered novel viral determinants of viral persistence, and a detailed characterization of rCl-13(GPC/VGKS) can provide novel insights into the mechanisms underlying persistent viral infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27581982      PMCID: PMC5105648          DOI: 10.1128/JVI.01303-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

Review 1.  Emerging infectious diseases and risk to the traveler.

Authors:  D O Freedman; J Woodall
Journal:  Med Clin North Am       Date:  1999-07       Impact factor: 5.456

2.  Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles.

Authors:  Ki Jeong Lee; Mar Perez; Daniel D Pinschewer; Juan Carlos de la Torre
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 3.  Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy.

Authors:  Elsa B Damonte; Celia E Coto
Journal:  Adv Virus Res       Date:  2002       Impact factor: 9.937

Review 4.  Exotic emerging viral diseases: progress and challenges.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

5.  Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus.

Authors:  Luis Martínez-Sobrido; Elina I Zúñiga; Debralee Rosario; Adolfo García-Sastre; Juan Carlos de la Torre
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Arenavirus nucleoproteins prevent activation of nuclear factor kappa B.

Authors:  W W Shanaka I Rodrigo; Emilio Ortiz-Riaño; Christelle Pythoud; Stefan Kunz; Juan C de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

7.  Plasmacytoid dendritic cells are productively infected and activated through TLR-7 early after arenavirus infection.

Authors:  Mónica Macal; Gavin M Lewis; Stefan Kunz; Richard Flavell; James A Harker; Elina I Zúñiga
Journal:  Cell Host Microbe       Date:  2012-06-14       Impact factor: 21.023

8.  Rapid activation of spleen dendritic cell subsets following lymphocytic choriomeningitis virus infection of mice: analysis of the involvement of type 1 IFN.

Authors:  Maria Montoya; Matthew J Edwards; Delyth M Reid; Persephone Borrow
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

9.  Z proteins of New World arenaviruses bind RIG-I and interfere with type I interferon induction.

Authors:  Lina Fan; Thomas Briese; W Ian Lipkin
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

10.  Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA.

Authors:  Lukas Flatz; Andreas Bergthaler; Juan Carlos de la Torre; Daniel D Pinschewer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

View more
  1 in total

1.  Biological Characterization of Conserved Residues within the Cytoplasmic Tail of the Pichinde Arenaviral Glycoprotein Subunit 2 (GP2).

Authors:  Hinh Ly; Yuying Liang; Junjie Shao; Qinfeng Huang; Xiaoying Liu; Da Di; Mythili Dileepan; Morgan Brisse
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.